GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Cash Flow from Investing

BioSpecifics Technologies (BioSpecifics Technologies) Cash Flow from Investing : $-33.53 Mil (TTM As of Sep. 2020)


View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2020, BioSpecifics Technologies spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $42.31 Mil on purchasing investments. It gained $26.69 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, BioSpecifics Technologies spent $15.61 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2020.


BioSpecifics Technologies Cash Flow from Investing Historical Data

The historical data trend for BioSpecifics Technologies's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies Cash Flow from Investing Chart

BioSpecifics Technologies Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.11 -16.69 -10.37 -11.46 -32.03

BioSpecifics Technologies Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.07 -15.31 6.14 -8.74 -15.61

BioSpecifics Technologies Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

BioSpecifics Technologies's Cash Flow from Investing for the fiscal year that ended in Dec. 2019 is calculated as:

BioSpecifics Technologies's Cash Flow from Investing for the quarter that ended in Sep. 2020 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioSpecifics Technologies  (NAS:BSTC) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

BioSpecifics Technologies's purchase of property, plant, equipment for the three months ended in Sep. 2020 was $0.00 Mil. It means BioSpecifics Technologies spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

BioSpecifics Technologies's sale of property, plant, equipment for the three months ended in Sep. 2020 was $0.00 Mil. It means BioSpecifics Technologies gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

BioSpecifics Technologies's purchase of business for the three months ended in Sep. 2020 was $0.00 Mil. It means BioSpecifics Technologies spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

BioSpecifics Technologies's sale of business for the three months ended in Sep. 2020 was $0.00 Mil. It means BioSpecifics Technologies gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

BioSpecifics Technologies's purchase of investment for the three months ended in Sep. 2020 was $-42.31 Mil. It means BioSpecifics Technologies spent {stock_data.stock.currency_symbol}}42.31 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

BioSpecifics Technologies's sale of investment for the three months ended in Sep. 2020 was $26.69 Mil. It means BioSpecifics Technologies gained $26.69 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

BioSpecifics Technologies's net Intangibles purchase and sale for the three months ended in Sep. 2020 was $0.00 Mil. It means BioSpecifics Technologies paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

BioSpecifics Technologies's cash from discontinued investing activities for the three months ended in Sep. 2020 was 0.00 Mil. It means BioSpecifics Technologies paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

BioSpecifics Technologies's cash from other investing activities for the three months ended in Sep. 2020 was $0.00 Mil. It means BioSpecifics Technologies paid $0.00 Mil for other investing activities.


BioSpecifics Technologies Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Traded in Other Exchanges
N/A
Address
35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Executives
Paul Gitman director 167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth director 191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman director, 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman director 43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N. director DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison officer: Chief Financial Officer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi director, officer: Chief Executive Officer 41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell officer: Principal Financial Officer C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law officer: SVP Business Development 23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman director, 10 percent owner, officer: President 1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487

BioSpecifics Technologies (BioSpecifics Technologies) Headlines

From GuruFocus